Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Incretins, insulin secretion and Type 2 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. White coat hypertension in early pregnancy in women with pre-existing diabetes: prevalence and pregnancy outcomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gluco-metabolic effects of oral and intravenous alcohol administration in men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
When glucose is taken orally, insulin secretion is stimulated much more than it is when glucose is infused intravenously so as to result in similar glucose concentrations. This effect, which is called the incretin effect and is estimated to be responsible for 50 to 70% of the insulin response to glucose, is caused mainly by the two intestinal insulin-stimulating hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Their contributions have been confirmed in mimicry experiments, in experiments with antagonists of their actions, and in experiments where the genes encoding their receptors have been deleted. In patients with Type 2 diabetes, the incretin effect is either greatly impaired or absent, and it is assumed that this could contribute to the inability of these patients to adjust their insulin secretion to their needs. In studies of the mechanism of the impaired incretin effect in Type 2 diabetic patients, it has been found that the secretion of GIP is generally normal, whereas the secretion of GLP-1 is reduced, presumably as a consequence of the diabetic state. It might be of even greater importance that the effect of GLP-1 is preserved whereas the effect of GIP is severely impaired. The impaired GIP effect seems to have a genetic background, but could be aggravated by the diabetic state. The preserved effect of GLP-1 has inspired attempts to treat Type 2 diabetes with GLP-1 or analogues thereof, and intravenous GLP-1 administration has been shown to be able to near-normalize both fasting and postprandial glycaemic concentrations in the patients, perhaps because the treatment compensates for both the impaired secretion of GLP-1 and the impaired action of GIP. Several GLP-1 analogues are currently in clinical development and the reported results are, so far, encouraging.
Original languageEnglish
JournalDiabetologia
Volume47
Issue number3
Pages (from-to)357-66
Number of pages10
ISSN0012-186X
DOIs
Publication statusPublished - 1 Mar 2004

ID: 32268666